Daria J. Hazuda
Daria Hazuda, Ph.D., trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral group as a Senior Research Biochemist at Merck in 1989.
Daria is currently Vice President of Infectious Disease and Vaccines at Merck Research Labs and Chief Scientific Officer of MRL Cambridge. Daria has over 30 years of experience in drug discovery and development with more than two hundred publications. She led the research efforts that identified the first-in class HIV integrase inhibitor Isentress which was awarded the Prix Galien in 2008 and was responsible for pioneering work on HCV drug resistance enabling the discovery of agents with improved spectrum and efficacy including the NS5A inhibitor Elbasvir and the NS3 inhibitor Grazoprevir which received the American Chemical Society Heroes of Chemistry Award in 2017. Daria has also been recognized with the Bernie Field Lecture Award, the David Barry DART Achievement Award for HIV Drug Development and is an elected Fellow of the American Society of Microbiology.